n-(3-(aminomethyl)benzyl)acetamidine has been researched along with Idiopathic Parkinson Disease in 2 studies
N-(3-(aminomethyl)benzyl)acetamidine: structure in first source
N-[3-(aminomethyl)benzyl]acetamidine : An aralkylamine that is Nbenzylacetamidine substituted at position 3 on the benzene ring by an aminomethyl group. An inhibitor of nitric oxide synthase.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brzozowski, MJ | 1 |
| Jenner, P | 1 |
| Rose, S | 1 |
| Gao, HM | 1 |
| Zhang, F | 1 |
| Zhou, H | 1 |
| Kam, W | 1 |
| Wilson, B | 1 |
| Hong, JS | 1 |
2 other studies available for n-(3-(aminomethyl)benzyl)acetamidine and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Inhibition of i-NOS but not n-NOS protects rat primary cell cultures against MPP(+)-induced neuronal toxicity.
Topics: Amidines; Animals; Antibodies, Monoclonal; Astrocytes; Benzylamines; Cell Count; Cells, Cultured; Do | 2015 |
Neuroinflammation and α-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease.
Topics: alpha-Synuclein; Amidines; Animals; Animals, Genetically Modified; Benzylamines; Disease Models, Ani | 2011 |